1. Volume 153, Issue 3, Pages 702-710 (September 2017)
Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease 
Derk C.F. Klatte, Alessandro Gasparini, Hong Xu, Pietro de Deco, Marco Trevisan, Anna L.V. Johansson, Björn Wettermark, Johan Ärnlöv, Cynthia J Janmaat, Bengt Lindholm, Friedo W. Dekker, Josef Coresh, Morgan E. Grams, Juan J. Carrero 
Gastroenterology 
Volume 153, Issue 3, Pages (September 2017)
DOI: /j.gastro
Copyright © 2017 AGA Institute Terms and Conditions

2. Figure 1
Subgroup analyses depicting the HR and 95% CI for the risk of doubling of serum creatinine (A) or >30% eGFR decline (B) associated with PPI vs H2B use.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2017 AGA Institute Terms and Conditions

3. Figure 2
HRs (and 95% CI) for the risk of doubling of serum creatinine (A) or >30% eGFR decline (B) associated with the cumulative use of PPIs. Histograms depict the proportion of participants across cumulative exposure strata. Cumulative exposure to PPI was calculated as the time-updated sum of DU since therapy initiation, which was modelled as a time-dependent variable in restricted cubic spline regressions. Five knots were set at 5th, 27.5th, 50th, 72.5th, and 95th percentiles of DDDs distribution. Hazards were adjusted for age, sex, eGFR at baseline, indications for acid-suppression therapy (gastroesophageal reflux disease, Barrett’s esophagus, ulcer disease, H pylori infection, and upper gastrointestinal tract bleeding), diabetes mellitus, hypertension, peripheral vascular disease, acute myocardial infarction, cerebrovascular disease, congestive heart failure, chronic obstructive pulmonary disease, and concomitant medications (NSAIDs, RAAS-inhibitors, beta blockers, calcium channel blockers, anti-thrombotics, statins, and diuretics). The lowest cumulative DU (0.50 mg) was used as the reference.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2017 AGA Institute Terms and Conditions